Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

By D. Kuhn, Qing Chen, P. Voorhees, John S. Strader, K. Shenk, Congcong Sun, S. Demo, M. Bennett, F. V. van Leeuwen, A. Chanan-Khan and 1 more. Blood, 2005

744 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/4ad7d37257b0750f4aaab96e83069c9e4ec7a736

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar

In Molecular Biology

1. Wenyi Wei
2. Lei Chen
3. T. Meng
4. Ping Wang
5. Lu Deng

In Oncology

1. S. Rajkumar

Citations in the corpus

• A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. (2012, background): “Prior lines of therapy, median (range) 5 (1-20)”
• A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis (2009, methodology): “We first determined the proteasome active site selectivity of PR-957 with a subunit-specific ELISA to quantify occupied proteasome active sites in intact cell”
• The role of ubiquitination in tumorigenesis and targeted drug discovery (2020, background): “Combined with lenalidomide and dexamethasone, carfilzomib achieves a near complete clinical response in naive MM patients.(477) In patients with relapsed/refractory MM, carfilzomib and dexamethasone (Kd56) demonstrate a longer PFS than that of bortezomib and dexamethasone (Vd).”